Paper2013115
Aminoglutethimide in advanced breast cancer: plasma levels and clinical results after low and high doses.
Strocchi E and 9 others. Cancer Chemother Pharmacol, 1991. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Aminoglutethimide in advanced breast cancer: plasma levels and clinical results after low and high doses. Papers, record 2013115. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2013115
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Aminoglutethimide in advanced breast cancer: plasma levels and clinical results after low and high doses.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Aminoglutethimide | Major topic |
| Breast Neoplasms | Major topic |
| Adult | |
| Aged | |
| Analysis of Variance | |
| Biological Availability | |
| Chromatography, High Pressure Liquid | |
| Cluster Analysis | |
| Discriminant Analysis | |
| Dose-Response Relationship, Drug | |
| Drug Administration Schedule | |
| Drug Evaluation | |
| Female | |
| Humans | |
| Middle Aged | |
| Regression Analysis | |
| Remission Induction |
Source PubMed
References16
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 4038654 | Low-dose aminoglutethimide without steroid replacement in the treatment of postmenopausal women with advanced breast cancer. | Eur J Cancer Clin Oncol | 1985 | https://conductscience.org/library/papers/4038654 | PubMed |
| 2 | 6221746 | Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer. | Br J Cancer | 1983 | https://conductscience.org/library/papers/6221746 | PubMed |
| 3 | 7044525 | Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. | Cancer Res | 1982 | https://conductscience.org/library/papers/7044525 | PubMed |
| 4 | 3978028 | Observations on the pharmacokinetics of low dose aminoglutethimide in patients with advanced breast cancer. | Br J Cancer | 1985 | https://conductscience.org/library/papers/3978028 | PubMed |
| 5 | 6177402 | Treatment of advanced breast cancer with aminoglutethimide: a 14-year experience. | Cancer Res | 1982 | https://conductscience.org/library/papers/6177402 | PubMed |
| 6 | 6765487 | Aminoglutethimide: review of pharmacology and clinical use. | Pharmacotherapy | 1981 | https://conductscience.org/library/papers/6765487 | PubMed |
| 7 | 2943339 | Aminoglutethimide as an inducer of microsomal enzymes. Part 1: Pharmacological aspects. | Breast Cancer Res Treat | 1986 | https://conductscience.org/library/papers/2943339 | PubMed |
| 8 | 6487491 | The effect of acetylator phenotype on the disposition of aminoglutethimide. | Br J Clin Pharmacol | 1984 | https://conductscience.org/library/papers/6487491 | PubMed |
| 9 | 6147642 | Low-dose aminoglutethimide in treatment of advanced breast cancer. | Lancet | 1984 | https://conductscience.org/library/papers/6147642 | PubMed |
| 10 | 3908116 | Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day. | Eur J Cancer Clin Oncol | 1985 | https://conductscience.org/library/papers/3908116 | PubMed |
| 11 | 7126424 | Polymorphically acetylated aminoglutethimide in humans. | Br J Cancer | 1982 | https://conductscience.org/library/papers/7126424 | PubMed |
| 12 | 6148221 | Metabolism of aminoglutethimide in humans. Identification of four new urinary metabolites. | Drug Metab Dispos | 1984 | https://conductscience.org/library/papers/6148221 | PubMed |
| 13 | 3742063 | Low dose aminoglutethimide (125 mg twice daily) with hydrocortisone for the treatment of advanced postmenopausal breast cancer. | Breast Cancer Res Treat | 1986 | https://conductscience.org/library/papers/3742063 | PubMed |
| 14 | 536467 | Serum aminoglutethimide levels: studies of serum half-life, clearance, and patient compliance. | J Clin Pharmacol | 1979 | https://conductscience.org/library/papers/536467 | PubMed |
| 15 | 4015950 | Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients. | Br J Cancer | 1985 | https://conductscience.org/library/papers/4015950 | PubMed |
| 16 | 3838134 | Metabolism of aminoglutethimide in humans: quantification and clinical relevance of induced metabolism. | Br J Cancer | 1985 | https://conductscience.org/library/papers/3838134 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 8354015 | Dose response evaluation. Use of plasma concentration confidence intervals as a tool to predict optimal drug dose ratio. | Clin Pharmacokinet | 1993 | https://conductscience.org/library/papers/8354015 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2013115
GET https://conductscience.org/api/papers/v1/2013115/authors